OSE Immunotherapeutics, a company member of the pole, announced an agreement with GERCOR, an independent non-profit French network of cancer specialists, to study Tedopi® in locally advanced or metastatic pancreatic cancer. GERCOR is finalizing the design of this Phase 2 trial of maintenance therapy with Tedopi® alone or combined with a PD-1 checkpoint inhibitor versus Folfiri*, in patients with stable disease after 4 months of standard chemotherapy with Folforinox**.
“We are pleased to have joined forces with such a prestigious oncology group as GERCOR to conduct the first study of Tedopi® in combination with a checkpoint inhibitor,” said Dominique Costantini, CEO of OSE. “We believe that Tedopi® may potentiate the activity of checkpoint inhibitors, enlarging the patient population who may benefit from them. We look forward to conducting this first combination study.”
Professor Christophe Louvet, President of GERCOR, added: “Tedopi®’s effects on the tumor micro-environment could make checkpoint inhibitors relevant for a larger percentage of patients. Our network is excited to have the opportunity to explore this new immuno-oncology pathway addressing a particularly aggressive cancer, and for which new therapeutic options are strongly needed.”
* Folfiri: combination chemotherapy with folinic acid, fluorouracil and irinotecan
** Folfirinox: combination chemotherapy with folinic acid, fluorouracil, irinotecan and oxaliplatin
You can find the press release in English here.
Find more information visit the website.